Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.70 USD
Change Today +0.66 / 5.98%
Volume 120.1K
TNDM On Other Exchanges
Symbol
Exchange
NASDAQ GM
NASDAQ GS
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

tandem diabetes care inc (TNDM) Snapshot

Open
$11.05
Previous Close
$11.04
Day High
$11.82
Day Low
$10.95
52 Week High
11/5/14 - $17.98
52 Week Low
07/7/15 - $10.14
Market Cap
351.2M
Average Volume 10 Days
119.7K
EPS TTM
$-3.11
Shares Outstanding
30.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TANDEM DIABETES CARE INC (TNDM)

tandem diabetes care inc (TNDM) Related Businessweek News

No Related Businessweek News Found

tandem diabetes care inc (TNDM) Details

Tandem Diabetes Care, Inc., a medical device company, focuses on the design, development, and commercialization of various products for people with insulin-dependent diabetes in the United States. The company offers t:slim insulin delivery system that comprises t:slim pump, its disposable insulin cartridge, and an infusion set; t:connect diabetes management application, a PC and Mac-compatible cloud-based data management application that provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and t:flex insulin delivery system that includes 480-unit disposable insulin cartridge and an infusion set. Its products in development include t:slim G4TM insulin pump with an Integrated CGM system; Odyssey Web-based software that allows users to update their pump’s software in their home environment; t:sport insulin delivery system; automated insulin delivery, an artificial pancreas system with external device, or combination of devices, intended to aid a person with insulin-dependent diabetes by automatically testing and controlling their blood glucose; and t:dual infusion systems with dual-chamber infusion pump for the management of diabetes. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

437 Employees
Last Reported Date: 02/24/15
Founded in 2006

tandem diabetes care inc (TNDM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $532.7K
Chief Financial Officer and Treasurer
Total Annual Compensation: $362.6K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $347.1K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $347.1K
Chief Administrative Officer
Total Annual Compensation: $275.2K
Compensation as of Fiscal Year 2014.

tandem diabetes care inc (TNDM) Key Developments

Tandem Diabetes Care, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015 ; Provides Earnings Guidance for the Year Ending December 31, 2015

Tandem Diabetes Care, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported sales of $15,706,000, operating loss of $18,671,000, net loss of $19,533,000 or $0.65 per basic and diluted share compared to the sales of $10,255,000, operating loss of $18,318,000, net loss of $19,197,000 or $0.83 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported sales of $28,014,000, operating loss of $39,081,000, net loss of $40,742,000 or $1.47 per basic and diluted share compared to the sales of $18,320,000, operating loss of $39,156,000, net loss of $41,159,000 or $1.79 per basic and diluted share for the same period a year ago. For the year ending December 31, 2015, the Company’s sales are estimated to be in the range of $70.0 million to $75.0 million, which includes $4.0 million to $6.0 million of t:flex Insulin Pump sales. Operating margin is estimated to be in the range of negative 100% to negative 110%, which includes approximately $13.0 million to $14.0 million in non-cash, stock-based compensation expense.

Tandem Diabetes Care Announces Development Agreement with Dexcom, Inc. for Integration of Future Generation Continuous Glucose Monitoring Systems

Tandem Diabetes Care, Inc. announced that it has entered into non-exclusive Development Agreements with Dexcom, Inc. to allow the integration of future generation Tandem insulin pumps with the Dexcom G5 and G6 continuous glucose monitoring (CGM) systems.

Tandem Diabetes Care, Inc. to Report Q2, 2015 Results on Jul 30, 2015

Tandem Diabetes Care, Inc. announced that they will report Q2, 2015 results After-Market on Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNDM:US $11.70 USD +0.66

TNDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.02 USD +0.38
Becton Dickinson and Co $142.83 USD -0.12
DexCom Inc $94.19 USD +0.45
Insulet Corp $29.71 USD +0.36
Smiths Group PLC 1,129 GBp +27.00
View Industry Companies
 

Industry Analysis

TNDM

Industry Average

Valuation TNDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.9x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TANDEM DIABETES CARE INC, please visit www.tandemdiabetes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.